Respire_final-01
  • CORPORATE
    • Company Overview
    • Company Management
    • Board of Directors
    • Scientific Team Leaders
    • Social Media Guidelines
  • NEUROTRANSMISSION
  • PHARMACEUTICAL CANNABINOIDS
    • Background
    • Pharmaceutical Cannabinoids
    • Obstructive Sleep Apnea
    • Dronabinol for the Treatment of Obstructive Sleep Apnea
    • Regulatory Process
  • NEUROMODULATORS
    • Ampakines
      • Lead Compounds
      • Attention Deficit Hyperactivity Disorder (ADHD)
      • Spinal Cord Injury (SCI)
      • Autism Spectrum Disorder (ASD)
    • GABAkines
      • Background
      • Epilepsy
      • Pain
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
  • CONTACT

Author: j3ff1

Home Articles Posted by j3ff1 (Page 4)
82 posts, 0 comments

RespireRx Pharmaceuticals Announces Publication of 2B PACE Study

November 30, 2017j3ff1
Read More

RespireRx Presentation at 2017 Rodman & Renshaw Conference on 09/12/17

September 8, 2017j3ff1
Read More

RespireRx Pharmaceuticals Inc. to Present at 2017 Rodman & Renshaw Conference

September 8, 2017j3ff1
Read More

RespireRx Pharmaceuticals Inc. Files June 30, 2017 Quarterly Report on Form 10-Q And Provides Update

August 25, 2017j3ff1
Read More

July 11, 2017j3ff1
Read More

Ampakines Executive Summary

July 11, 2017j3ff1
Read More

Dronabinol Executive Summary

July 11, 2017j3ff1
Read More

Ampakines Platform

July 11, 2017j3ff1
Read More

Cannabinoid Platform

July 11, 2017j3ff1
Read More

06/16/17 – RespireRx presentation at 2017 Marcum MicroCap Conference

June 16, 2017j3ff1
Read More

Posts navigation

< 1 2 3 4 5 6 7 … 9 >

Neurotransmission

  • Neurotransmission
©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.